Before the Pre-Submission: Why a Scoped Regulatory Memo Accelerates Pathway Clarity
Pre-Submission meetings with CDRH are a well-established mechanism for obtaining FDA's preliminary views on regulatory pathway, study design, and submission content. They are also a meaningful investment — in preparation time, internal resources, and the opportunity cost of a meeting slot. For development-stage companies facing a binary pathway question, an intermediate step belongs first.
Pre-Submission Preparation Assumes the Pathway Is Known
Pre-Submission meeting packages produce their best results when the applicant holds a clear working hypothesis about the regulatory pathway and seeks FDA's reaction to that hypothesis. When the pathway itself is unresolved — when a novel technology falls plausibly under more than one classification category — a premature Pre-Submission returns inconclusive feedback, or narrows the applicant's options before the analysis is complete.
The case for engaging CDRH early is one we have made before: early FDA engagement is the single biggest lever available to de-risk a development roadmap. This is the step that makes that engagement productive rather than exploratory.
A One-Issue Regulatory Memo Resolves the Threshold Question
A regulatory memo scoped to a single question — which pathway applies, and on what basis — provides the analytical foundation for a more productive Pre-Submission. The memo draws on FDA's published classification regulations, guidance documents, product codes, and precedent decisions to establish the most defensible pathway for the specific technology.
The Value for Investors and Development Planning
Pathway clarity carries value beyond regulatory planning. For companies raising capital or negotiating strategic partnerships, a documented regulatory assessment supports investor due diligence and informs development timelines. The difference between a 510(k) and a De Novo pathway, or between a De Novo and a PMA, drives time to market, clinical evidence requirements, and capital needs.
What an investor said about this
In Episode 3 of Quality in the Boardroom™, we put the question to an investor directly. Shannon Bean, Principal at CEI Ventures, described a Pre-Submission meeting as hard to earn — and said a company holding one has demonstrated a clear path forward. She was equally direct about the reverse: a company arriving without validation, clinical evidence, or a regulatory strategy reads to her as a team that has not yet reckoned with what bringing a product to market requires.
Watch Episode 3: How Capital Shapes the Future of MedTech →
CEI Ventures is an investor in QMB, Inc., co-presenter of Quality in the Boardroom™.
One Practical Consideration
A one-issue memo is not a substitute for a Pre-Submission meeting; it is preparation for one. Companies that arrive at CDRH with a well-reasoned pathway hypothesis have more focused interactions than those using the meeting to resolve foundational questions. It is also worth planning past the first meeting — a single Pre-Submission is rarely enough to de-risk a major launch, and the memo makes each subsequent meeting sharper than the last.
MedTech Impact Partners offers one-issue regulatory memos as structured Pre-Submission preparation.
Talk to the FDA, before you talk to the FDA™